Click for best price

Nononcology Biopharmaceuticals Market Size, Share 2022

Market Analysis and Insights: Global Nononcology Biopharmaceuticals Market

The global Nononcology Biopharmaceuticals market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nononcology Biopharmaceuticals market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nononcology Biopharmaceuticals market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nononcology Biopharmaceuticals market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nononcology Biopharmaceuticals market.

Global Nononcology Biopharmaceuticals Scope and Market Size

Non-oncology Biopharmaceuticals market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Non-oncology Biopharmaceuticals market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Biologics

Biosimilars

Segment by Application

Immunology

Endocrinology

Others

By Region

North America

United States

Canada

Europe

Germany

France

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Roche

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Novartis

Merck

Teva

Eli Lilly

Bristol-Myers Squibb

GlaxoSmithKline

UCB Pharma

Amgen

AbbVie

Takeda

AstraZeneca

Mylan

LEO Pharma

Boehringer Ingelheim

Alexion Pharmaceuticals

Elusys Therapeutics

Swedish Orphan Biovitrum

Biogen

The information for each competitor/Company Profile includes:

Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Nononcology Biopharmaceuticals product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Nononcology Biopharmaceuticals, with price, sales, revenue, and global market share of Nononcology Biopharmaceuticals from 2019 to 2022.

Chapter 3, the Nononcology Biopharmaceuticals competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Nononcology Biopharmaceuticals breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Nononcology Biopharmaceuticals market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Nononcology Biopharmaceuticals.

Chapter 13, 14, and 15, to describe Nononcology Biopharmaceuticals sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

Estimates 2022-2027 2021-2025 Nononcology Biopharmaceuticals Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
Market dynamics scenario, along with growth opportunities of the market in the years to come
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes	Report Details
Report Title	Global Non-oncology Biopharmaceuticals Market Research Report 2022
Historical Year	2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year	2021
Forecast Year	2029
Number of Pages	108 Pages
Customization Available	Yes, the report can be customized as per your need.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2017-2028)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Region
2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2017-2022)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028)
2.3 Non-oncology Biopharmaceuticals Market Dynamics
2.3.1 Non-oncology Biopharmaceuticals Industry Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2017-2022)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2017-2022)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2021
3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2017-2022)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2017-2022)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2017-2028)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2017-2028)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2017-2028)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2017-2028)
9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2017-2028)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.2.5 Sanofi Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.4.5 Pfizer Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Detail
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.5.5 Novo Nordisk Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.6.5 Novartis Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.7.5 Merck Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.8.5 Teva Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Detail
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.9.5 Eli Lilly Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.11.5 GlaxoSmithKline Recent Development
11.12 UCB Pharma
11.12.1 UCB Pharma Company Detail
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.12.5 UCB Pharma Recent Development
11.13 Amgen
11.13.1 Amgen Company Detail
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.13.5 Amgen Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Detail
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.14.5 AbbVie Recent Development
11.15 Takeda
11.15.1 Takeda Company Detail
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.15.5 Takeda Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Detail
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.16.5 AstraZeneca Recent Development
11.17 Mylan
11.17.1 Mylan Company Detail
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.17.5 Mylan Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Detail
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.18.5 LEO Pharma Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Detail
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.20.5 Alexion Pharmaceuticals Recent Development
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Detail
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.21.5 Elusys Therapeutics Recent Development
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Detail
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.22.5 Swedish Orphan Biovitrum Recent Development
11.23 Biogen
11.23.1 Biogen Company Detail
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.23.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Biologics
Table 3. Key Players of Biosimilars
Table 4. Global Non-oncology Biopharmaceuticals Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 5. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Non-oncology Biopharmaceuticals Market Share by Region (2017-2022)
Table 8. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Non-oncology Biopharmaceuticals Market Share by Region (2023-2028)
Table 10. Non-oncology Biopharmaceuticals Market Trends
Table 11. Non-oncology Biopharmaceuticals Market Drivers
Table 12. Non-oncology Biopharmaceuticals Market Challenges
Table 13. Non-oncology Biopharmaceuticals Market Restraints
Table 14. Global Non-oncology Biopharmaceuticals Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Non-oncology Biopharmaceuticals Market Share by Players (2017-2022)
Table 16. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021)
Table 17. Ranking of Global Top Non-oncology Biopharmaceuticals Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Non-oncology Biopharmaceuticals Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-oncology Biopharmaceuticals Product Solution and Service
Table 21. Date of Enter into Non-oncology Biopharmaceuticals Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-oncology Biopharmaceuticals Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2017-2022)
Table 25. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2023-2028)
Table 27. Global Non-oncology Biopharmaceuticals Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2017-2022)
Table 29. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2023-2028)
Table 31. North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
Table 33. Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
Table 34. Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
Table 35. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2017-2022) & (US$ Million)
Table 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region (2023-2028) & (US$ Million)
Table 37. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
Table 38. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
Table 39. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022) & (US$ Million)
Table 40. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028) & (US$ Million)
Table 41. Roche Company Detail
Table 42. Roche Business Overview
Table 43. Roche Non-oncology Biopharmaceuticals Product
Table 44. Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 45. Roche Recent Development
Table 46. Sanofi Company Detail
Table 47. Sanofi Business Overview
Table 48. Sanofi Non-oncology Biopharmaceuticals Product
Table 49. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 50. Sanofi Recent Development
Table 51. Johnson & Johnson Company Detail
Table 52. Johnson & Johnson Business Overview
Table 53. Johnson & Johnson Non-oncology Biopharmaceuticals Product
Table 54. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 55. Johnson & Johnson Recent Development
Table 56. Pfizer Company Detail
Table 57. Pfizer Business Overview
Table 58. Pfizer Non-oncology Biopharmaceuticals Product
Table 59. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Novo Nordisk Company Detail
Table 62. Novo Nordisk Business Overview
Table 63. Novo Nordisk Non-oncology Biopharmaceuticals Product
Table 64. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 65. Novo Nordisk Recent Development
Table 66. Novartis Company Detail
Table 67. Novartis Business Overview
Table 68. Novartis Non-oncology Biopharmaceuticals Product
Table 69. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Merck Company Detail
Table 72. Merck Business Overview
Table 73. Merck Non-oncology Biopharmaceuticals Product
Table 74. Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 75. Merck Recent Development
Table 76. Teva Company Detail
Table 77. Teva Business Overview
Table 78. Teva Non-oncology Biopharmaceuticals Product
Table 79. Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 80. Teva Recent Development
Table 81. Eli Lilly Company Detail
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Non-oncology Biopharmaceuticals Product
Table 84. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 85. Eli Lilly Recent Development
Table 86. Bristol-Myers Squibb Company Detail
Table 87. Bristol-Myers Squibb Business Overview
Table 88. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product
Table 89. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 90. Bristol-Myers Squibb Recent Development
Table 91. GlaxoSmithKline Company Detail
Table 92. GlaxoSmithKline Business Overview
Table 93. GlaxoSmithKline Non-oncology BiopharmaceuticalsProduct
Table 94. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 95. GlaxoSmithKline Recent Development
Table 96. UCB Pharma Company Detail
Table 97. UCB Pharma Business Overview
Table 98. UCB Pharma Non-oncology BiopharmaceuticalsProduct
Table 99. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 100. UCB Pharma Recent Development
Table 101. Amgen Company Detail
Table 102. Amgen Business Overview
Table 103. Amgen Non-oncology BiopharmaceuticalsProduct
Table 104. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 105. Amgen Recent Development
Table 106. AbbVie Company Detail
Table 107. AbbVie Business Overview
Table 108. AbbVie Non-oncology BiopharmaceuticalsProduct
Table 109. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 110. AbbVie Recent Development
Table 111. Takeda Company Detail
Table 112. Takeda Business Overview
Table 113. Takeda Non-oncology BiopharmaceuticalsProduct
Table 114. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 115. Takeda Recent Development
Table 116. AstraZeneca Company Detail
Table 117. AstraZeneca Business Overview
Table 118. AstraZeneca Non-oncology BiopharmaceuticalsProduct
Table 119. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 120. AstraZeneca Recent Development
Table 121. Mylan Company Detail
Table 122. Mylan Business Overview
Table 123. Mylan Non-oncology BiopharmaceuticalsProduct
Table 124. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 125. Mylan Recent Development
Table 126. LEO Pharma Company Detail
Table 127. LEO Pharma Business Overview
Table 128. LEO Pharma Non-oncology BiopharmaceuticalsProduct
Table 129. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 130. LEO Pharma Recent Development
Table 131. Boehringer Ingelheim Company Detail
Table 132. Boehringer Ingelheim Business Overview
Table 133. Boehringer Ingelheim Non-oncology BiopharmaceuticalsProduct
Table 134. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 135. Boehringer Ingelheim Recent Development
Table 136. Alexion Pharmaceuticals Company Detail
Table 137. Alexion Pharmaceuticals Business Overview
Table 138. Alexion Pharmaceuticals Non-oncology BiopharmaceuticalsProduct
Table 139. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 140. Alexion Pharmaceuticals Recent Development
Table 141. Elusys Therapeutics Company Detail
Table 142. Elusys Therapeutics Business Overview
Table 143. Elusys Therapeutics Non-oncology BiopharmaceuticalsProduct
Table 144. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 145. Elusys Therapeutics Recent Development
Table 146. Swedish Orphan Biovitrum Company Detail
Table 147. Swedish Orphan Biovitrum Business Overview
Table 148. Swedish Orphan Biovitrum Non-oncology BiopharmaceuticalsProduct
Table 149. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 150. Swedish Orphan Biovitrum Recent Development
Table 151. Biogen Company Detail
Table 152. Biogen Business Overview
Table 153. Biogen Non-oncology BiopharmaceuticalsProduct
Table 154. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022) & (US$ Million)
Table 155. Biogen Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-oncology Biopharmaceuticals Market Share by Type: 2021 VS 2028
Figure 2. Biologics Features
Figure 3. Biosimilars Features
Figure 4. Global Non-oncology Biopharmaceuticals Market Share by Application in 2021 & 2028
Figure 5. Immunology Case Studies
Figure 6. Endocrinology Case Studies
Figure 7. Others Case Studies
Figure 8. Non-oncology Biopharmaceuticals Report Years Considered
Figure 9. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Non-oncology Biopharmaceuticals Market Share by Region: 2021 VS 2028
Figure 12. Global Non-oncology Biopharmaceuticals Market Share by Players in 2021
Figure 13. Global Top Non-oncology Biopharmaceuticals Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-oncology Biopharmaceuticals as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2021
Figure 15. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 16. North America Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
Figure 17. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
Figure 21. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Region (2017-2028)
Figure 29. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Latin America Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
Figure 37. Mexico Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Middle East & Africa Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2017-2028)
Figure 41. Turkey Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Saudi Arabia Non-oncology Biopharmaceuticals Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 44. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 45. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 46. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 47. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 48. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 49. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 50. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 51. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 54. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 55. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 56. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 57. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 58. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 59. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 60. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 61. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 62. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 63. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 64. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 65. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

DOWNLOAD SAMPLE

Download
Free Sample

Request
Customization

Check
Discount

REPORT PURCHASE OPTIONS

Single User Price : $2762

Multi User Price : $4143

Enterprise Price : $5524

---- OR ----

Frequently Asked Questions ?

Delivery Time

Upto 24 hrs - Working days
Upto 48 hrs max - Weekends and public holidays

User License

Single User License
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

Multi user License
A license granted to multiple users.

Site License
A license granted to a single business site/establishment.

Corporate License, Global License
A license granted to all employees within organisation access to the product.

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

Our Key Features

Data Accuracy and Reliability
Data Security
Customized Research
Trustworthy
Competitive Offerings

Global Non-oncology Biopharmaceuticals Market Research Report 2022